Background: Management of type 2 diabetes is not uniform. The aim of the study was to assess diabetes care delivery and status of long-term diabetes related complications.
Introduction
Estimates in 2015 indicate that approximately 8.5%, equivalent to 78.3 million, of the adult population living in South East Asia (SEA) region suffer from type 2 diabetes mellitus (T2DM). SEA region also witnessed 24.2% of all live births affected by high blood glucose during pregnancy. The projected increase of DM population in SEA, to 140.2 million by 2040, is a major threat to public health resources. 1, 2 Urbanisation, change in lifestyle and high life expectancy are cited as reasons for the increasing prevalence of T2DM. 3 Bangladesh rank second in T2DM prevalence among SEA countries. Saquib et al (2012) in a meta-analysis of studies conducted between 1995 and 2010, showed continuous increase in pooled T2DM prevalence at the rate of 3.8% (1995) (1996) (1997) (1998) (1999) (2000) , 5 .3% (2001) (2002) (2003) (2004) (2005) , and 9.0% (2006) (2007) (2008) (2009) (2010) . (4) Currently, 7.1 million people are affected with T2DM in Bangladesh, turning it into 10 th highest T2DM burden country in the world. 1 IDF atlas (2015) projects 13.6 million adults in Bangladesh to suffer from T2DM by 2040. 1 This staggering toll of T2DM and its complications has also increased the total disability adjusted life years (DALYs) by nearly 70% between 1990 and 2010 in Bangladesh, which is much higher than DALYs attributed to cardiovascular disease and cancer (25%). 5 This has led to high economic cost, productivity losses and intangible cost (psychological pain to the family and loved ones), past human suffering. 2 Strategies to improve diabetes care, thereby mitigating diabetes-related complications are urgently needed. Early screening in high risk groups and proper management is recommended to avoid early complications. A regular audit of diabetes management is an essential step towards the prevention and control. 6 Periodic evaluations help in assessing the usefulness of measures taken and also depict seriousness of the policies towards global commitment in accordance with the World Health Organization's action plan, en route to achieving long and healthy life. 7 The DiabCare, a series of cross-sectional observational studies, was started in Europe in 1990s with the collaboration of Novo Nordisk. The primary goal of these studies was to appraise the performance of diabetes care system through participation of large number of patients and clinicians over time. This survey, was not limited to the evaluation of diabetes management, but has also explored the psychological aspect of participating patients. 8 DiabCare Asia was initiated in 1997 in 6 countries including Bangladesh. 9 (9) DiabCare Bangladesh 1998 and 2008 have informed healthcare policy and influenced diabetes management programmes in the country. 10, 11 Consistent with previous studies, DiabCare Bangladesh 2012 was performed to describe diabetes management, control and complications. It also evaluated the associated primary and secondary preventive efforts and treatment adherence in patients with T2DM living in Bangladesh.
Methods

Study design and setting
An observational, non-interventional, cross-sectional design was used for this study (Universal trial number (UTN): U1111-1137-2729). The study was conducted between June 2013 to September 2013 at 80 secondary care and 20 tertiary care hospitals in Bangladesh. All aspects of the study were conducted in accordance with the Declaration of Helsinki 12 and the Guidelines for Good Pharmacoepidemiology Practice (GPP), 13 supervised by study investigators and their deputies. Due to the observational nature of this study, there were no study-specific visits or investigational products and patients were treated according to routine clinical practice at the discretion of the attending physician.
Study participants
Patients routinely visiting the centre during the study period were screened for eligibility. Before any studyrelated activity, investigators or their deputies gave eligible patients comprehensible oral and written information about the study and obtained informed consent. Adults over the age of 18 years with T2DM on non-pharmacological or pharmacological treatment who had been at the centre for at least one year and had visited the centre within the last 3-6 months were included, if they provided informed consent. Patients who had previously participated in the study, had suspected or confirmed pregnancy or were unable to comply with protocol requirements were excluded from the study. Patients were permitted to withdraw from the study at will at any time. Recruitment and enrolment continued until the target number of patients was reached.
Study endpoints
The primary endpoint of the study was defined as the proportion of patients with glycosylated haemoglobin (HbA1c) less than 7% (53 mmol/mol) at study entry. 14 (14) This was chosen as the primary endpoint due to the validity of HbA1c as an indicator of diabetes care. The secondary endpoints were: duration of diabetes, duration and type of treatment, other measures of glycaemic control (fasting plasma glucose (FPG) and post-prandial glucose (PPG), lipid control (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and fasting triglycerides), presence of known risk factors or diabetes-related complications (dyslipidaemia, hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy, and diabetic eye complications), hypoglycaemia, and treatment adherence. Potential predictor variables including age, gender, body mass index (BMI), diabetes duration, hypertension, insulin therapy, use of multiple oral antidiabetic agents (OADs), HbA1c, FPG and performance of self-measurement of blood glucose (SMBG) were analysed for their relationship with various complications.
Data sources and measurement
Relevant data were collected from patients' medical records and recorded in case report forms (CRFs) designed for this study. Data collected included demography, medical history, complications, eye and foot examinations, diabetes management and most recent laboratory investigations performed within the past one year. Blood samples were collected for HbA1c measurement. The decision of lab selection, supervision and quality assurance of the centralized measurements were performed by Bangladesh institute of research and rehabilitation in diabetes, endocrine and metabolic disorders (BIRDEM). The blood samples were stored between 2°C to 8°C. HbA1c was measured through venous/capillary blood as per NGSP guidelines (National Glycosylated Standardisation Programme) using BioRad HPLC (High Performance Liquid Chromatography) D 10 or Variant 2 method. Blood samples were stored only for retest purpose and promptly disposed after the completion of the HbA1c analysis. In addition, patients were asked to complete a treatment adherence questionnaire and a hypoglycaemia questionnaire which were administered by investigators or their deputies. The treatment adherence questionnaire included patient adherence to diet, exercise, taking medication as prescribed, performance of SMBG testing and keeping appointments with healthcare professionals. The hypoglycaemia questionnaire assessed symptoms of hypoglycaemia categorised as mild (sweating, dizziness, trembling, tingling in the hands, feet or lips, blurred vision, difficulty in concentrating, palpitations and occasional headache); moderate (odd behaviour such as rudeness or laughter, bad temper or moodiness, aggressive behaviour, confusion); severe (loss of consciousness or needing help from another person); or nocturnal (any symptoms between bedtime and breakfast). The hypoglycaemia questionnaire also assessed patient responses to hypoglycaemia including SMBG testing, snacking, skipping or changing medication doses, visiting hospital and patient concern.
Patient information collected for this study was kept confidential and measures such as encryption were enforced to protect patient identity. Sensitive patient data were kept with investigators according to local regulations regarding personal data protection.
Study size
The study aimed to enrol a total of 2092 patients from Bangladesh. The sample size was based on published data and consultation with local external experts. The prevalence of cardiovascular disease (CVD) was used as a basis for the study size target because available literature suggests that this is the least prevalent of all diabetic complications and its use confers the maximum possible representativeness to the sample size estimate. Assuming a CVD prevalence of 2%, a sample of 2092 patients conforms to a 5% level of significance and 30% margin of error.
Statistical analysis
The full analysis set (FAS) included all patients with at least one data point. Missing data was not replaced. The data analysis was performed using SAS, Version [9.2] . Continuous variables were summarised using descriptive statistics: mean ± standard deviation (SD), median (range), and number missing. Categorical variables were presented as number and percentages (%). Percentages were based on all patients in the respective patient set regardless of whether they had non-missing values or not.
The influence of potential predictor variables on outcome variables (any diabetes complications) were evaluated by analysis of covariance (ANCOVA) for continuous variables, and by logistic regression for categorical variables. The following predictor variables were assessed separately in the univariate analyses: age, sex, BMI, duration of diabetes, hypertension, insulin therapy, use of multiple OADs, HbA1c, FPG and SMBG (testing done or not done). In a second step, all risk factors were included in the multivariate analysis and a backward stepwise regression method was used to identify significant predictors. Three of the variablesage, gender and duration of diabetes were retained in each final model to allow for adjustment of their effects. For continuous predictors, odds ratio estimates for a change in 1 unit were presented with corresponding 95% confidence intervals and two-sided p-values. For categorical predictors, odds ratio estimates between categories were presented with corresponding 95% confidence intervals and two-sided p-values.
Results
Patient characteristics and demographics
2092 participants with mean age of 51.3±11.0 years, 49.8% male and 50.2% female, were enrolled in this study. The largest ethnic group was Bangladeshi (n=2084, 99.6%). Majority of patients belonged to lower middle income group (n=1156, 55.3%) and had family history of DM (n=1286, 61.5%). The median duration of T2DM was 6 (min 1: max 37) years. Approximately one third, (n=766, 36.6%) of patients led a sedentary lifestyle and mean waist circumference was 87.2±9.5 cm (Table I) . (Table III) . 56.4% patients were hypertensive with only 50.8% taking anti-hypertensive medication. The mean systolic and diastolic blood pressure was 124.4±12.0 and 80.0±6.9 mmHg respectively. The most frequently used anti-hypertensive medications were angiotensin-II receptor blockers (ARBs) (35.5%) and angiotensinconverting enzyme (ACE) inhibitors (30.9%) ( Table III) . Duration of diabetes, higher BMI and higher HbA1c were predictive for both hypertension and dyslipidemia. 
Diabetes-related complications
The most commonly seen diabetes related complications were peripheral neuropathy (39.0%) and eye complications (21.7%). The proportion of patients with cardiovascular (CV), renal, foot complications, and erectile dysfunction were 16.8%, 13.4%, 11.4% and 15.8% respectively. Approximately 34.6% had been screened for renal complications in past two years. The most commonly encountered renal complication was microalbuminuria (10.0%) followed by gross proteinuria (4.0%). Cataract (9.0%) and nonproliferative diabetic retinopathy (8.7%) were the most common eye complications. Angina was the most frequently reported CV complication and 2.7% of T2DM patients had amputation. (Table- All continuous data are presented as mean ± standard deviation and median (range). Percentage (%) values calculated from total non-missing.
Treatment adherence
A large proportion of patients were non-adherent to clinical recommendations regarding diet (52.3%), exercise (65.4%) and self-testing (74.5%). Around one third (32.2%) of patients were non-compliant to their prescribed medications and even substantial proportion of patients (51.0%) did not completely adhere to scheduled appointments with healthcare professionals.
Hypoglycaemia
The incidences of mild, moderate, severe and nocturnal hypoglycaemia reported within the past three months were 33.5%, 9.3%, 3.0% and 8.8%, respectively (Table  VII) . More than half of patients (54.7%) indicated their concerns about hypoglycaemia. Among patients who experienced hypoglycaemia, 80.3% either never checked their blood glucose or checked occasionally. Small proportion of patients (9.3%) measured their blood glucose frequently for a few days following an episode. Most of the patients (82.7%) never visited a hospital, or visited on rare instances after hypoglycaemic episodes. 45.3% had performed SMBG over the past year, at a median frequency of 2.0 (1.0"30.0) times in the past month. In addition, 70.2% patients started snacking between meals and even a substantial proportion of patients (31.6%) skipped or reduced their diabetes medications because of hypoglycaemia.
Quality of life
Though patients' responses to the EQ-5D questionnaire were collected, the use of a modified version of the EQ-5D form violated the user agreement with the instrument owner (EuroQol group) and rendered the data unsuitable for analysis.
Discussion
DiabCare Bangladesh 2012 more competently describes diabetes care currently being delivered, the challenges associated with improving care and the future role of diabetes prevention. It has enrolled relatively higher patients (2092) as compared to previous DiabCare studies. 10 , The mean age of the patients (51.3 years) is consistent with previous DiabCare and other studies conducted in Bangladesh. 10, 16 The patients in this study had relatively shorter disease duration (6 years) as compared to DiabCare 2008 (7.9 years). Greater proportion of patients with family history of diabetes (61.5% vs. 52.8%) and smoking habits (11.3% vs. 8.2%) has been observed as compared to DiabCare 2008 study. The increasing incidence of risks emphasise the need of primary prevention programs for T2DM management in Bangladesh.
Using multiple diagnostic criteria, as assessed by centralized HbA1c, FPG and PPG measurements, DiabCare Bangladesh 2012 showed unsatisfactory glycaemic control in majority of patients surveyed.
The mean HbA1c of 8.4% is similar to two previous DiabCare studies of 2008 (8.6%) and 1998 (7.9%). 10,11 Islam et al (2015) also recently demonstrated mean HbA1c of 8.3% in 515 T2DM patients. 17 The proportion of patients with poor glycaemic control (HbA1c e"7.0%) within this cohort is comparable (77.5%) to the DiabCare 2008 (76.9%), but greater than that of 1998 study (63.3%). 10, 11 The median FPG is also consistent with DiabCare 2008 study (8.4±2.7 mmol/L). 10 Sultana et al found mean FPG levels of 8.9±3.6 mmol/L in a prospective study from a tertiary care setting (n=140) in Bangladesh. 16 10 Increased frequency of insulin users reflects more aggressive management strategy adopted in Bangladesh in T2DM patients as recommended by previous DiabCare studies. The United Kingdom Prospective Diabetes Studies (UKPDS) has also showed that the control of glycaemia was maintained in 50% of T2DM patients, who had been getting insulin treatment for over 6 years. 22 However still a large proportion of patients have not met target HbA1c or blood glucose levels in the current DiabCare.
Higher proportion of T2DM patients had hypertension (56.4%) as compared to 2008 and 1998 study (47% vs. 35.8%). However, proportion of dyslipidemia is consistent with DiabCare 1998 and 2008 Bangladesh studies. 10, 11 Results also showed older age, HbA1c, and FPG to be associated with higher odds of dyslipidaemia and hypertension. Efforts to control blood glucose levels as well as cardiovascular risk factors such as lipids or hypertension is imperative for successful management of T2DM.
The findings of this study need to be interpreted in light of the study limitations. Firstly, due to the cross-sectional observational nature of the study, it is not possible to completely exclude the effect of selection bias and also to draw conclusions on the impact of treatment. Secondly, as all centres offered specialised diabetes care services, patients attending these centres, who were eligible for enrolment in the study, may not be representative of the country as a whole. Thirdly, data on treatment adherence and hypoglycaemia were selfreported, and the estimates may have been subject to recall bias. Further, due to the retrospective collection of laboratory findings aside from HbA1c, it was not possible to fully assess the status of glycaemic and lipid control in the entire study population. Nevertheless, the relatively large numbers of patients with available laboratory results do allow for relative valid observations to be drawn.
Conclusion
DaibCare 2012 has emphasized that still a large proportion of patients with T2DM in Bangladesh have unsatisfactory glycaemic and metabolic control, high prevalence of complications and suboptimal treatment adherence. The complexities and intricacies of providing quality diabetes care are challenging. Understanding the importance of comprehensive care and implementing the quality measures will help track progress and guide improvement. The study supports the current efforts of healthcare professionals towards diabetes care to bring down HbA 1 C <7% among Diabetics and demand aggressive strategies for high risk patients to prevent Diabetes. Improving awareness among health professionals and diabetic subjects with intensive education programs is also recommended.
